298 related articles for article (PubMed ID: 12582019)
1. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.
Baron AT; Cora EM; Lafky JM; Boardman CH; Buenafe MC; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):103-13. PubMed ID: 12582019
[TBL] [Abstract][Full Text] [Related]
2. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
3. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
[TBL] [Abstract][Full Text] [Related]
4. A preliminary study of serum concentrations of soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid hormones in healthy men and women.
Baron AT; Lafky JM; Suman VJ; Hillman DW; Buenafe MC; Boardman CH; Podratz KC; Perez EA; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2001 Nov; 10(11):1175-85. PubMed ID: 11700266
[TBL] [Abstract][Full Text] [Related]
5. Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer.
Baron AT; Wilken JA; Haggstrom DE; Goodrich ST; Maihle NJ
IDrugs; 2009 May; 12(5):302-8. PubMed ID: 19431095
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the prognostic value of soluble epidermal growth factor receptor plasma concentration in advanced non-small-cell lung cancer patients.
Jantus-Lewintre E; Sirera R; Cabrera A; Blasco A; Caballero C; Iranzo V; Rosell R; Camps C
Clin Lung Cancer; 2011 Sep; 12(5):320-7. PubMed ID: 21729651
[TBL] [Abstract][Full Text] [Related]
7. Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer.
Petri AL; Høgdall E; Christensen IJ; Kjaer SK; Blaakaer J; Høgdall CK
APMIS; 2006 May; 114(5):359-63. PubMed ID: 16725012
[TBL] [Abstract][Full Text] [Related]
8. Screening and detection of ovarian cancer.
Breedlove G; Busenhart C
J Midwifery Womens Health; 2005; 50(1):51-4. PubMed ID: 15637515
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of CA 125 in ovarian cyst fluid of patients with epithelial ovarian cancer.
Kolwijck E; Span PN; Thomas CM; Bulten J; Sweep FC; Massuger LF
Oncol Rep; 2010 Feb; 23(2):579-84. PubMed ID: 20043124
[TBL] [Abstract][Full Text] [Related]
10. Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole.
Lafky JM; Baron AT; Cora EM; Hillman DW; Suman VJ; Perez EA; Ingle JN; Maihle NJ
Cancer Res; 2005 Apr; 65(8):3059-62. PubMed ID: 15833834
[TBL] [Abstract][Full Text] [Related]
11. [Serum level and expression of vascular epithelial growth factor in ovarian epithelial carcinoma].
Sun LX; Wu Y; Han HQ; Wang QH
Ai Zheng; 2003 Jan; 22(1):58-61. PubMed ID: 12561438
[TBL] [Abstract][Full Text] [Related]
12. Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer.
Camlica H; Duranyildiz D; Tas F; Yasasever V
Am J Clin Oncol; 2008 Dec; 31(6):585-8. PubMed ID: 19060592
[TBL] [Abstract][Full Text] [Related]
13. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer.
Müller V; Witzel I; Pantel K; Krenkel S; Lück HJ; Neumann R; Keller T; Dittmer J; Jänicke F; Thomssen C
Anticancer Res; 2006; 26(2B):1479-87. PubMed ID: 16619561
[TBL] [Abstract][Full Text] [Related]
15. Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group study.
Burger RA; Darcy KM; DiSaia PJ; Monk BJ; Grosen EA; Gatanaga T; Granger GA; Wang J; Tian C; Hanjani P; Cohn DE
Cancer; 2004 Jul; 101(1):106-15. PubMed ID: 15221995
[TBL] [Abstract][Full Text] [Related]
16. Serum C-reactive protein in the differential diagnosis of ovarian masses.
Hefler-Frischmuth K; Hefler LA; Heinze G; Paseka V; Grimm C; Tempfer CB
Eur J Obstet Gynecol Reprod Biol; 2009 Nov; 147(1):65-8. PubMed ID: 19619929
[TBL] [Abstract][Full Text] [Related]
17. Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer.
Drenberg CD; Saunders BO; Wilbanks GD; Chen R; Nicosia RF; Kruk PA; Nicosia SV
Gynecol Oncol; 2010 Apr; 117(1):117-24. PubMed ID: 20071014
[TBL] [Abstract][Full Text] [Related]
18. Detection of serum transforming growth factor-alpha in patients of primary epithelial ovarian cancers by enzyme immunoassay.
Chien CH; Huang CC; Lin YH; Shen J; Chow SN
Gynecol Oncol; 1997 Sep; 66(3):405-10. PubMed ID: 9299253
[TBL] [Abstract][Full Text] [Related]
19. Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection.
Erkanli A; Taylor DD; Dean D; Eksir F; Egger D; Geyer J; Nelson BH; Stone B; Fritsche HA; Roden RB
Cancer Res; 2006 Feb; 66(3):1792-8. PubMed ID: 16452240
[TBL] [Abstract][Full Text] [Related]
20. Serum protein markers for early detection of ovarian cancer.
Mor G; Visintin I; Lai Y; Zhao H; Schwartz P; Rutherford T; Yue L; Bray-Ward P; Ward DC
Proc Natl Acad Sci U S A; 2005 May; 102(21):7677-82. PubMed ID: 15890779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
